VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

VERAXA’s shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp.

ZURICH, SWITZERLAND – March 2, 2026 — VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting (“EGM”) on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the “Business Combination”) among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC.

The merger will be carried out by means of an absorption merger. Veraxa Biotech Holding AG, as the acquiring company, will take over VERAXA as the transferring company and simultaneously change its name to Veraxa Biotech AG. VERAXA will continue to operate under its existing management team led by Chief Executive Officer, Christoph Antz. Additionally, the EGM approved an ordinary capital increase of a maximum of CHF 223,400.00 and offering the corresponding number of shares to the shareholders of Voyager in connection with the business combination.

“We appreciate our shareholders’ support and their approval to take the next steps in our business combination process with Voyager”, said Christoph Antz, Ph.D., Chief Executive Officer of VERAXA. “VERAXA is well-positioned to generate significant long-term value by addressing the growing need for safer and more effective cancer therapies with a focus on antibody-drug conjugates and bispecific T cell engagers. We look forward to continuing our path to becoming a leading innovator in cancer medicine.”

Subject to the approval of Voyager’s shareholders, VERAXA and Voyager will commence final procedures towards closing the Business Combination and the expected trading of shares of the combined company on NASDAQ under the symbol “VRXA”. The resolutions of the EGM are subject to the condition of the approval of the Business Combination by Voyager’s shareholders.

About the Business Combination

On April 22, 2025,VERAXA entered into a definitive business combination agreement (the “Business Combination Agreement“) with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH,”Voyager”).  Upon closing of the Business Combination, the combined company is expected to become a publicly traded company listed on NASDAQ trading under the symbol “VRXA”.

The description of the Business Combination contained herein is only a high-level summary and is qualified in its entirety by reference to the underlying documents filed with the Securities and ExchangeCommission (the “SEC”). A more detailed description of the terms of the transaction has been provided in a proxy statement/prospectus filed with theSEC by Voyager on February 19, 2026.

Note to Shareholders of VERAXA Biotech AG

In preparation for the registration of shares and subsequent share trading, we ask all shareholders of VERAXA Biotech AG to do the following:

• To prepare your registration within the US share register, please send us your current email address to info@veraxa.com by March 6, 2026.
• Please ensure that your shares are or will be registered by your bank with the Computershare share register.
• To avoid short selling, please ensure that your shares are not used for lending by your bank.

About VERAXA Biotech

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the EuropeanMolecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For more information, please visit www.veraxa.com.

On April 22, 2025, VERAXA entered into a definitive business combination agreement (the “Business Combination Agreement”) with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector(NASDAQ: VACH, “Voyager”).  Upon closing of the Business CombinationAgreement, VERAXA is expected to become a publicly traded company listed onNASDAQ.

About Voyager Acquisition Corp.

Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry. For more information, please visit https://www.voyageracq.com